Loading clinical trials...
Loading clinical trials...
A Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ICP-248 as Monotherapy or in Combination With Anti-CD20 Monoclonal Antibody in Patients With Mature B-cell Malignancies
Conditions
Interventions
ICP-248
Obinutuzumab (G)
+1 more
Locations
8
United States
BRCR Medical Center
Plantation, Florida, United States
Clinical Research Alliance
Westbury, New York, United States
Pan American Center for Oncology Trials
San Juan, Puerto Rico
CNE CCOHTPC of Cherkasy Regional Council
Cherkasy, Ukraine
CNE"City Clin Hosp#4"of Dnipro City Council
Dnipro, Ukraine
Medical Center of Limited Liability Company Arensia Exploratory Medicine
Kyiv, Ukraine
Start Date
April 23, 2024
Primary Completion Date
June 25, 2027
Completion Date
October 25, 2027
Last Updated
June 19, 2025
Lead Sponsor
InnoCare Pharma Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions